Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say

The recent readout of SKYSCRAPER-01 (NCT04294810) filled in details about the phase 3 trial for tiragolumab, an anti-TIGIT antibody, which failed to make a meaningful difference when combined with atezolizumab (Tecentriq, Genentech/Roche) for untreated patients with non–small cell lung cancer (NSCLC).¹ At first glance, the results confirm pharma’s current verdict: T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a bust as a target for immune checkpoint regulation.